TQB0 Stock Chart & Stats
€1.12
-€0.07(-5.88%)
At close: 4:00 PM EDT
€1.12
-€0.07(-5.88%)
Day’s Range― - ―
52-Week Range€0.84 - €2.80
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€52.54M
Enterprise Value€49.84
Total Cash (Recent Filing)€11.33M
Total Debt (Recent Filing)€3.52M
Price to Earnings (P/E)―
Beta1.36
Next Earnings
Sep 10, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.31
Shares Outstanding46,987,297
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)6.39
Price to Sales (P/S)4.89
P/FCF Ratio-5.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€4.40Price Target Upside292.43% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.22
Revenue Forecast (FY)€17.98M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained near-60% gross margins reflect a high-value, IP-driven product mix (HYFT/ReefIQ/LensAI) that separates cost of goods from scalable software and data services. If recurring platform adoption grows, these margin levels enable durable operating leverage and stronger cash conversion over time.
Emerging Recurring SaaS Revenue & ReefIQ LaunchSecuring initial enterprise LensAI contracts and launching ReefIQ mark a structural shift toward recurring revenue and platform monetization. Over months, converting clients from fee-for-service to subscription models would increase revenue predictability, customer lifetime value, and the compounding value of MindWalk's HYFT biological substrate.
AMD Partnership & Major Throughput GainsJoint engineering with AMD delivered order-of-magnitude throughput and cost improvements, lowering marginal discovery costs and enabling scale. These durable infrastructure efficiencies strengthen competitive differentiation for regulated, compute‑intensive life‑science workloads and support higher margins as SaaS usage scales.
Bears Say
Persistent Net Losses & Equity ErosionLarge, ongoing losses that materially erode shareholders' equity are a structural concern: continued negative retained earnings limits financial flexibility, raises dilution or refinancing risks, and constrains investments needed to scale the SaaS transition without materially altering capital structure.
Negative Operating Cash Flow & Substantial Cash BurnConsistent negative operating and free cash flow mean the business consumes cash as it grows, increasing dependency on external or nondilutive funding. With modest cash on hand relative to planned commercial and R&D investments, cash burn is a durable execution risk that can force delays or change strategic priorities.
Recurring Revenue Immature & SaaS Compute Economics UncertainThe long-term promise of high-margin SaaS relies on scaling ReefIQ/LensAI and controlling compute costs. Early-stage recurring revenue and unclear per-client compute economics create structural uncertainty in future gross margins and revenue predictability until adoption and unit economics are demonstrated at scale.
MindWalk Holdings News
TQB0 FAQ
What was MindWalk Holdings’s price range in the past 12 months?
MindWalk Holdings lowest stock price was €0.84 and its highest was €2.80 in the past 12 months.
What is MindWalk Holdings’s market cap?
MindWalk Holdings’s market cap is €52.54M.
When is MindWalk Holdings’s upcoming earnings report date?
MindWalk Holdings’s upcoming earnings report date is Sep 10, 2026 which is in 39 days.
How were MindWalk Holdings’s earnings last quarter?
MindWalk Holdings released its earnings results on Jul 22, 2026. The company reported -€0.049 earnings per share for the quarter, missing the consensus estimate of -€0.045 by -€0.005.
Is MindWalk Holdings overvalued?
According to Wall Street analysts MindWalk Holdings’s price is currently Undervalued.
Does MindWalk Holdings pay dividends?
MindWalk Holdings does not currently pay dividends.
What is MindWalk Holdings’s EPS estimate?
MindWalk Holdings’s EPS estimate is -0.05.
How many shares outstanding does MindWalk Holdings have?
MindWalk Holdings has 46,987,297 shares outstanding.
What happened to MindWalk Holdings’s price movement after its last earnings report?
MindWalk Holdings reported an EPS of -€0.049 in its last earnings report, missing expectations of -€0.045. Following the earnings report the stock price went down -12.397%.
Which hedge fund is a major shareholder of MindWalk Holdings?
Currently, no hedge funds are holding shares in DE:TQB0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MindWalk Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€4.40 (292.43% Upside)
€4.40 (292.43% Upside)
Blogger Sentiment
Neutral
DE:TQB0 Sentiment 67%
Sector Average ―
Sector Average ―
Technicals
SMA
Negative
20 days / 200 days
Momentum
-41.12%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-51.19%
Trailing 12-Months
Company Description
MindWalk Holdings
MindWalk Holdings Corp. functions as an innovative bio-native artificial intelligence firm. Its core mission involves leveraging the synergy of AI, comprehensive multi-omics data, and sophisticated laboratory investigations to accelerate the identification and advancement of biological therapeutics. Utilizing its proprietary LensAI platform and HYFT technology, the company forges partnerships with pharmaceutical and biotechnology enterprises. These collaborations are designed to diminish the inherent risks associated with drug development and to unlock new possibilities for treatments. Founded in 1983, the company adopted its current name, MindWalk Holdings Corp., in September 2025, having previously been known as ImmunoPrecise Antibodies Ltd. Its corporate headquarters are located in Austin, Texas.
TQB0 Company Deck
TQB0 Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a materially improved operational and commercial trajectory: revenue grew 46% with expanding gross margins, net loss was more than halved year-over-year, the company secured its first recurring platform contracts, launched ReefIQ, filed IP extensions, and demonstrated major infrastructure gains via the AMD partnership. However, the recurring revenue is still not material, the company remains unprofitable with a sizeable net loss (~$14–15M), operating expenses are increasing on a comparable basis and cash is modest relative to planned investments. On balance the progress, validation and strategic moves (patent, AMD engineering, Russell inclusion, FDA-linked client approval and nondilutive divestiture proceeds) outweigh the near-term financial challenges and execution risks.View all DE:TQB0 earnings summariesTQB0 Stock 12 Month Forecast
Average Price Target
€4.40
▲(292.43% Upside)
Technical Analysis
XBiotech
―
Relmada Therapeutics
―
PMV Pharmaceuticals
―
Werewolf Therapeutics
―
Estrella Immunopharma
―